About Us

Pioneering the first dedicated therapeutic for HCM.

Heart Metabolics Limited is pioneering a pharmaceutical therapy for the treatment of hypertrophic cardiomyopathy (“HCM”).

HCM is an inherited heart condition in which the contracting mechanism of the heart cell is defective. This leads to deleterious heart muscle thickening and a situation in which the heart is unable to pump enough blood to the rest of the body. Although about 600,000 people in the US alone have the gene that places them at risk for HCM, it often goes undiagnosed because many people with the disease have few if any symptoms and can lead normal lives with no significant problems. However, in about 20% of these people, the condition can cause symptoms which include shortness of breath with exercise, chest pain, or problems with the heart’s electrical system. Sometimes these symptoms may be severe or even fatal.

Unfortunately, the younger the individual is when diagnosed with HCM, the more likely that the individual has a severe form.

Although various cardiovascular drugs are currently used to treat HCM, none of them are specifically indicated for the condition, and many patients are not being helped by current therapeutics. In response to this medical need and based on encouraging phase II clinical trial results to date, Heart Metabolics is developing perhexiline as a therapeutic for all types of HCM. Perhexiline is currently an approved drug in Australia and New Zealand for the treatment of angina.

Heart Metabolics plans to conduct clinical trials in the U.S. and seek FDA approval of perhexiline as an orphan drug; the company currently has such an orphan designation from the FDA.

Investors

venBio
brandon_logo
Seroba_Lifesciences-Logo
AshHill_Logo

Leadership with proven experience

Leadership

William Daly

President & CEO

Mr. Daly has over 20 years of management experience encompassing business development operations, investment banking, and corporate and securities law at both public and private companies. Prior to joining Heart Metabolics, Mr. Daly served as Senior Vice President of Operations & Business Development of Puma Biotechnology (NYSE: PBYI). Prior to that, Mr. Daly served as Chief Business Officer at Akebia Therapeutics (Nasdaq: AKBA) and Aerpio Therapeutics, served as Vice President of Business Development at Halozyme Therapeutics and served as Senior Vice President of Business Development at Cougar Biotechnology where he was responsible for the auction process that resulted in the $1 billion acquisition of Cougar by Johnson & Johnson. He co-led the integration of Cougar and J&J and was also Site Head of the Los Angeles facility, which conducted two phase 3 trials of Cougar’s prostate cancer drug, abiraterone acetate (approved and launched as Zytiga®). In addition to the above, Mr. Daly has held senior executive positions at Allergan, Chiron and Novartis. Mr. Daly began his career practicing corporate and securities law and was also an investment banker, most recently serving as a Managing Director for Prudential Vector Healthcare Group. Mr. Daly graduated from UC Berkeley with a degree in biochemistry and received his law degree and his MBA from UCLA.

Ian Howes

Chief Financial Officer

Mr. Howes has over 20 years of experience in senior financial roles developing early stage life sciences companies. During his career, he has completed numerous rounds of private and public equity and debt transactions, including two initial public offerings. Also, he has successfully managed multiple M&A transactions, including the sale of Scioderm to Amicus Therapeutics in 2015 and the sale of Serenex to Pfizer in 2008. Prior to joining Heart Metabolics, Mr. Howes was CFO of Scioderm, a pediatric orphan disease company. Between 2009 and 2013, Mr. Howes was CFO for Akebia Therapeutics (Nasdaq: AKBA), a biotechnology company developing pharmaceutical drugs for anemia and ophthalmology.  Prior to that, Mr. Howes spent five years serving as CFO and Senior VP Corporate Development of Serenex, an integrated discovery and development oncology company. Prior to that, Mr. Howes served as CFO and VP Operations at Paradigm Genetics (Nasdaq: PDGM). Mr. Howes began his professional career with Coopers & Lybrand in London. He is a Chartered Accountant and has an MBA from the Kenan-Flagler Business School at the University of North Carolina at Chapel Hill.

Charlotte Hartman, PharmD

Vice President, Clinical Development

Dr. Hartman has over 15 years of experience in pharmaceutical drug development, clinical program strategy, global trial execution, and global regulatory submissions. Prior to joining Heart Metabolics, Dr. Hartman held several senior positions at Akebia Therapeutics, most recently as Vice President of Clinical Development, where she was responsible for the clinical development of vadadustat, a novel therapy for the treatment of anemia of chronic kidney disease. Earlier, she held a senior position at Targanta Therapeutics as well as several positions at Pharmacia & Upjohn (later Pfizer), where she was an integral member of the teams that led the clinical development and major regulatory submissions in both the US and Europe with Zyvox® (linezolid), the first in a new class of antibacterials, and Orbactiv® (oritavancin), a novel semisynthetic lipoglycopeptide. Before entering the pharmaceutical industry, Dr. Hartman was the head of clinical pharmacy services at North Austin Medical Center in Austin, Texas as well as serving as chairperson and board member on several independent and institutional review boards. Dr. Hartman received her Doctorate of Pharmacy degree from the University of Texas and her Bachelor of Science in Pharmacy from The State University of New York at Buffalo.

Mark Midei, MD

Executive Director, Head of Cardiology

Dr. Midei has been a clinical and regulatory consultant to Heart Metabolics, since its founding.  He is also founding member of AshHill Investments, a private equity investment group specializing in emerging and early stage pharmaceutical companies.  He has also served as a consultant to a number of biotech pharmaceutical, medical device, and information systems companies.  Dr. Midei completed Internship and Residency on the Osler Medical Service from 1981-1984, and Fellowships in Cardiovascular Disease, Interventional Cardiology and Pacing from 1984-1987, all at the Johns Hopkins Hospital.  He then began his career as an academic cardiologist at The Johns Hopkins University School of Medicine where he served on the faculty in Cardiology from 1987-1995.  In 1995, Dr. Midei was a founding member of Midatlantic Cardiovascular Associates in central Maryland.  This group became the dominant provider of cardiovascular care in the region, and Dr. Midei served as Medical Director of its Clinical Research Division.  Dr. Midei has served as the principal investigator on dozens of pharmaceutical and medical device trials at all phases of development.  He is the author of more than 100 peer-reviewed scientific presentations and publications.  Dr. Midei received combined BS/MD degree in 1981 from Kent State University and Northeastern Medical University in Ohio.

Our Board

Corey Goodman, PhD

Chairman

Dr. Goodman is a Managing Partner at venBio. He was formerly President of Pfizer's Biotherapeutics and Bioinnovation Center, and a member of Pfizer's Executive Leadership Team, where he oversaw the discovery and development of biotherapeutics as well as innovative new technologies. Dr. Goodman co-founded Exelixis, Renovis, Second Genome, and Ossianix prior to joining venBio. He is former professor at Stanford University and University of California Berkeley, co-founder of Berkeley's Wills Neuroscience Institute, Investigator with the Howard Hughes Medical Institute, and currently is Adjunct Professor at UC San Francisco. Dr. Goodman is an elected member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences, and the American Philosophical Society. His honors include, amongst others, the Alan T. Waterman Award, Canada Gairdner Biomedical Award, March of Dimes Prize in Developmental Biology, Reeve-Irvine Research Medal, and Dawson Prize in Genetics. Among his public policy roles, Dr. Goodman is Chair of the California Council on Science and Technology, advising the Governor and State Legislature, and former Chair of the National Research Council's Board on Life Sciences, advising the Federal Government. Dr. Goodman is Chair of the Board of Solstice Biologics, and Second Genome. He also serves on the boards of Adheren, Alexo Therapeutics, Checkmate Pharmaceuticals and the Pacific Institute.

Robert Adelman, MD

Dr. Adelman is a founder and Managing Partner at venBio. He was formerly a Private Equity Partner at OrbiMed Advisors where he was part of a team that invested $1.1B in both private and public companies across three venture capital funds. Dr. Adelman has co-founded a number of biotechnology companies. He led Fund I's investments into Aragon Pharmaceuticals where he joined the Board of Directors, and remained on the Board until the company's acquisition by Johnson and Johnson. He also led the investment into Seragon Pharmaceuticals where he joined the Board of Directors, and remained on the Board until the company's acquisition by Genentech/Roche. Dr. Adelman serves on the Boards of Alexo Therapeutics, Apellis Pharmaceuticals, Metacrine Sciences, Precision Biosciences and Solstice Biologics.  Dr. Adelman received his undergraduate degree from University of California at Berkeley, his medical degree from Yale University, performed his residency at Cornell University Medical Center, and practiced surgery in New York and New Jersey.

Alan O’Connell, PhD

Dr. O’Connell is a Partner at Seroba Life Sciences. He has a background in product and business development in the pharmaceutical and biotechnology industries. Prior to joining Seroba, Dr. O’Connell worked in a variety of product and business development roles at Elan Corporation (Dublin), American Biogenetic Sciences, Inc. (New York), and in the Pharmacovigilance section at the Medicines and Healthcare Products Regulatory Agency (London). His previous venture capital experience was gained at Estée Lauder Investments (New York) and he is on the scientific advisory board of the Lauder funded Alzheimer’s Drug Discovery Foundation. Dr. O’Connell serves on the Boards of Ario Pharma, Crescent Diagnostics, Opsona Therapeutics, Veryan Medical and Xention. Dr. O’Connell graduated with a Ph.D. (neuropharmacology) from the National University of Ireland, Galway in 1994 and has a Master’s degree in pharmacology from the University of London (1990). He carried out post-doctoral neuroscience research at University College, Dublin and has published in several scientific journals.

Stephen Thompson, PhD

Dr. Thompson is a founding partner of Brandon Capital Partners. Previously, Dr. Thompson worked with Bio Innovation SA and helped establish Terra Rossa Capital. Prior to this, he was a Director of Apax Partners, a leading international private equity group based in London. Before joining Apax Partners, he fulfilled roles in product development with a UK biotechnology company, Cantab Pharmaceuticals. Earlier, Dr. Thompson spent ten years as a research immunologist in London and California. Dr. Thompson serves on the Boards of Auspherix, Elastagen, Longas, Vaxxas and is a Council Member of the Australian Venture Capital Association Limited (AVCAL). Dr. Thompson received an Honors degree in Immunology and Biochemistry, a PhD in Immunology from Kings College London and an MBA, specializing in Entrepreneurship, from Imperial College London. He is a Graduate of the Australian Institute of Company Directors.

William Daly

President & CEO

Mr. Daly has over 20 years of management experience encompassing business development operations, investment banking, and corporate and securities law at both public and private companies. Prior to joining Heart Metabolics, Mr. Daly served as Senior Vice President of Operations & Business Development of Puma Biotechnology (NYSE: PBYI). Prior to that, Mr. Daly served as Chief Business Officer at Akebia Therapeutics (Nasdaq: AKBA) and Aerpio Therapeutics, served as Vice President of Business Development at Halozyme Therapeutics and served as Senior Vice President of Business Development at Cougar Biotechnology where he was responsible for the auction process that resulted in the $1 billion acquisition of Cougar by Johnson & Johnson. He co-led the integration of Cougar and J&J and was also Site Head of the Los Angeles facility, which conducted two phase 3 trials of Cougar’s prostate cancer drug, abiraterone acetate (approved and launched as Zytiga®). In addition to the above, Mr. Daly has held senior executive positions at Allergan, Chiron and Novartis. Mr. Daly began his career practicing corporate and securities law and was also an investment banker, most recently serving as a Managing Director for Prudential Vector Healthcare Group. Mr. Daly graduated from UC Berkeley with a degree in biochemistry and received his law degree and his MBA from UCLA.

Sean Gallagher

Mr. Gallagher is CEO and co-founder of Clyde Real Estate, a leading Irish commercial property firm. Mr. Gallagher co-founded and was CEO of Smarthomes, Ireland’s largest home technology company, for which he won the Deloitte Fast 50, Rising Star Award and was a finalist in the Ernst & Young Entrepreneur of the Year Awards. With a long-standing commitment to helping support job creation in Ireland, Mr. Gallagher has spent more than 20 years training and mentoring hundreds of start-up companies and emerging entrepreneurs including serving as A/CEO of one of Ireland’s County Enterprise Boards. He was previously appointed by the Irish Government to serve on a number of State Boards, including the North / South trade body, and Intertrade Ireland, which promotes economic co-operation across the island of Ireland. There, he served as Chair of the Board’s Equity Network Initiative helping to promote Venture Capital and Angel Investment in early stage businesses. Mr. Gallagher serves on the Boards of App Factory Consulting, Clyde Pharma, Clyde Real Estate Property Group, HWT Engineering and GSN Nutrition. Mr. Gallagher graduated with an MBA from the University of Ulster.